Form 4: Recursion Pharmaceuticals Executive Najat Khan Reports Stock Option Grant and RSU Vesting

Najat Khan, Chief R&D Commercial Officer at Recursion Pharmaceuticals, reported the acquisition of stock options and restricted stock units (RSUs) in a recent SEC filing.

Summary

• Najat Khan, Chief R&D Commercial Officer at Recursion Pharmaceuticals, filed a Form 4 with the SEC.
• The filing reports the acquisition of 993,944 stock options with an exercise price of $7.34, vesting over time starting July 1, 2025, and expiring August 1, 2034.
• Khan also acquired 496,972 Class A Common Stock units through RSU vesting, with the first quarter vesting on August 15, 2025, and subsequent vesting quarterly thereafter.
• Following these transactions, Khan directly owns 496,972 shares of Class A Common Stock and 993,944 stock options.
• The transactions were reported on August 1, 2024.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. It reflects standard executive compensation practices and aligns executive interests with shareholders.

Positives

• The grant of stock options and RSUs to a key executive like Najat Khan aligns her interests with those of the shareholders.
• The vesting schedules for both the options and RSUs incentivize continued service and contribution to the company's success.

Industry Context

Form 4 filings are routine disclosures required by the SEC to ensure transparency in insider trading activities. They provide insights into the compensation structures and equity ownership of company executives.

Stakeholder Impact

• Shareholders may view the stock option and RSU grants as a positive sign, aligning management's interests with the company's long-term success.
• Employees may be motivated by the fact that key executives are incentivized to improve company performance.

Key Dates